Ampersand Biomedicines
Dhiman Das currently serves as Senior Scientist I at Ampersand Biomedicines, a position held since November 2022, following the role of Scientist II at the same company. Previously, Dhiman worked as a Research & Development Scientist specializing in Microfluidics at Allozymes, focusing on designing proprietary microfluidic setups and chips for directed evolution. Academic experience includes serving as a Research Fellow at Nanyang Technological University, where research involved on-chip microbubble generation for in-vivo imaging, along with a tenure as a Teaching Assistant, instructing on mass transfer and analytical chemistry. Earlier roles include Graduate Research Assistant at Tezpur University and Process Engineer at Vedanta Resources. Dhiman holds a PhD in Chemical and Biomolecular Engineering from Nanyang Technological University and a B.Tech in Chemical Engineering from the National Institute of Technology Durgapur.
This person is not in any offices
Ampersand Biomedicines
Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.